Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

The earnings call summary reflects a mixed outlook with a negative bias. Financial performance shows a decline in net sales and adjusted EBITDA, indicating challenges in revenue and earnings. Despite some positive growth in medical imaging and improved gross profit, the overall financial health is strained by increased tax expenses and customer order volatility. The Q&A section did not clarify uncertainties, adding to the negative sentiment. Given these factors, the stock price is likely to experience a negative movement in the near term.
The earnings call reveals several negative factors: a 9.5% decline in net sales, increased net cash used in operating activities, and a negative trailing 12-month EBITDA. Although there are improvements in gross profit margin and adjusted EBITDA, these are overshadowed by inefficiencies and revenue impacts from facility closures and production transfers. The Q&A session provided no additional insights. Overall, the negative financial performance and operational challenges suggest a likely negative stock price movement.
The earnings call reveals several concerning factors: a significant decrease in net sales and gross profit margins, negative adjusted EBITDA, and customer order headwinds. Despite some cost structure optimizations and a focus on long-term growth, the immediate financial performance and operational challenges are likely to outweigh these positives. The lack of a share repurchase program and negative cash flow further contribute to a negative outlook. Consequently, the stock price is expected to experience a negative movement in the range of -2% to -8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.